Development and Validation of a Robust RP-HPLC Method for the Quantification of Piroxicam in Topical Gel Formulations: Assessing Analytical Performance

Piroxicam is a prominent pain reliever that’s accessible in a wide range of dosage forms such as tablets, ointments, and gel. Formerly, multiple approaches for active therapeutic ingredients and tablet dosage forms have been developed. According to the review of the literature, no approaches for piroxicam gel dosage form have been developed. Piroxicam in gel dosage form was estimated using a Reverse phase high-performance liquid chromatography (RP-HPLC) method that is fast, responsive, reliable, and affordable. The analytical method was developed using a Kromacil C18 column (250 × 4.6mm 5 µ with a 25mM KH₂PO₄ buffer (pH 3.0) and acetonitrile (ACN) during the mobile phase in a (60:40v/v) ratio at 1.0mL/min. The eluent was detected at 325nm using a UV-Visible detection device. Piroxicam elutes after 5.525 minutes. The suggested approach provides linearity of concentration from 4.00 to 12.01 µg/mL, with an r² value of 0.9998. According to ICH requirements, this method was evaluated for process accuracy, specificity, linearity, dependability, robustness, and ruggedness.